Sichuan Hebang Biotechnology Corporation Limited (603077.SS)
CNY 1.69
(0.0%)
CNY 1.69
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 459.06 Million CNY | -56.18% |
| 2022 | 1.04 Billion CNY | 115.52% |
| 2021 | 486.11 Million CNY | 6.15% |
| 2020 | 457.93 Million CNY | -33.51% |
| 2019 | 688.68 Million CNY | 0.32% |
| 2018 | 686.47 Million CNY | 23.28% |
| 2017 | 556.83 Million CNY | 17.73% |
| 2016 | 472.97 Million CNY | 55.94% |
| 2015 | 303.3 Million CNY | 35.95% |
| 2014 | 223.1 Million CNY | 17.95% |
| 2013 | 189.14 Million CNY | 3.38% |
| 2012 | 182.97 Million CNY | -11.93% |
| 2011 | 207.74 Million CNY | 6.09% |
| 2010 | 195.81 Million CNY | 47.2% |
| 2009 | 133.03 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 145.8 Million CNY | -20.81% |
| 2024 Q3 | 143.74 Million CNY | 81.31% |
| 2024 Q2 | 79.27 Million CNY | -45.63% |
| 2023 Q3 | 127.17 Million CNY | 24.28% |
| 2023 Q4 | 184.11 Million CNY | 44.77% |
| 2023 FY | 459.06 Million CNY | -56.18% |
| 2023 Q1 | 140.25 Million CNY | -51.29% |
| 2023 Q2 | 102.33 Million CNY | -27.04% |
| 2022 Q2 | 265.26 Million CNY | 23.55% |
| 2022 FY | 1.04 Billion CNY | 115.52% |
| 2022 Q4 | 287.91 Million CNY | 2.89% |
| 2022 Q1 | 214.7 Million CNY | 160.7% |
| 2022 Q3 | 279.81 Million CNY | 5.49% |
| 2021 Q3 | 169.43 Million CNY | 52.82% |
| 2021 Q4 | 82.35 Million CNY | -51.39% |
| 2021 FY | 486.11 Million CNY | 6.15% |
| 2021 Q1 | 123.44 Million CNY | 2367.02% |
| 2021 Q2 | 110.87 Million CNY | -10.18% |
| 2020 Q2 | 157.37 Million CNY | -1.48% |
| 2020 Q3 | 135.81 Million CNY | -13.7% |
| 2020 Q4 | 5 Million CNY | -96.32% |
| 2020 FY | 457.93 Million CNY | -33.51% |
| 2020 Q1 | 159.74 Million CNY | -22.99% |
| 2019 FY | 688.68 Million CNY | 0.32% |
| 2019 Q4 | 207.43 Million CNY | 18.44% |
| 2019 Q1 | 134.46 Million CNY | -40.94% |
| 2019 Q2 | 171.64 Million CNY | 27.66% |
| 2019 Q3 | 175.14 Million CNY | 2.04% |
| 2018 Q3 | 175.91 Million CNY | 12.94% |
| 2018 FY | 686.47 Million CNY | 23.28% |
| 2018 Q4 | 227.67 Million CNY | 29.42% |
| 2018 Q2 | 155.75 Million CNY | 22.53% |
| 2018 Q1 | 127.12 Million CNY | -25.17% |
| 2017 Q1 | 117.77 Million CNY | -24.31% |
| 2017 Q2 | 129.24 Million CNY | 9.73% |
| 2017 Q3 | 139.94 Million CNY | 8.28% |
| 2017 Q4 | 169.87 Million CNY | 21.38% |
| 2017 FY | 556.83 Million CNY | 17.73% |
| 2016 Q2 | 112.66 Million CNY | 16.97% |
| 2016 FY | 472.97 Million CNY | 55.94% |
| 2016 Q4 | 155.6 Million CNY | 43.55% |
| 2016 Q1 | 96.31 Million CNY | 3.33% |
| 2016 Q3 | 108.39 Million CNY | -3.79% |
| 2015 Q2 | 85.46 Million CNY | 127.63% |
| 2015 Q4 | 93.21 Million CNY | 7.04% |
| 2015 Q3 | 87.07 Million CNY | 1.89% |
| 2015 Q1 | 37.54 Million CNY | -48.31% |
| 2015 FY | 303.3 Million CNY | 35.95% |
| 2014 FY | 223.1 Million CNY | 17.95% |
| 2014 Q3 | 51.42 Million CNY | -3.33% |
| 2014 Q1 | 45.85 Million CNY | -41.93% |
| 2014 Q4 | 72.63 Million CNY | 41.25% |
| 2014 Q2 | 53.19 Million CNY | 16.0% |
| 2013 FY | 189.14 Million CNY | 3.38% |
| 2013 Q2 | 42.31 Million CNY | 16.97% |
| 2013 Q3 | 31.68 Million CNY | -25.13% |
| 2013 Q1 | 36.17 Million CNY | -47.06% |
| 2013 Q4 | 78.96 Million CNY | 149.24% |
| 2012 Q2 | 46.56 Million CNY | 26.23% |
| 2012 Q4 | 68.34 Million CNY | 119.25% |
| 2012 Q1 | 36.89 Million CNY | -51.02% |
| 2012 Q3 | 31.17 Million CNY | -33.07% |
| 2012 FY | 182.97 Million CNY | -11.93% |
| 2011 FY | 207.74 Million CNY | 6.09% |
| 2011 Q3 | 44.88 Million CNY | 0.0% |
| 2011 Q4 | 75.32 Million CNY | 67.81% |
| 2010 FY | 195.81 Million CNY | 47.2% |
| 2009 FY | 133.03 Million CNY | 0.0% |